Gilead Sciences, Inc. (GILD) Holdings Lifted by Alps Advisors Inc.
Alps Advisors Inc. grew its position in Gilead Sciences, Inc. (NASDAQ:GILD) by 8.2% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 25,689 shares of the biopharmaceutical company’s stock after purchasing an additional 1,949 shares during the period. Alps Advisors Inc.’s holdings in Gilead Sciences were worth $2,081,000 as of its most recent SEC filing.
Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Migdal Insurance & Financial Holdings Ltd. acquired a new stake in shares of Gilead Sciences in the 2nd quarter worth approximately $147,000. Hanson & Doremus Investment Management lifted its stake in shares of Gilead Sciences by 806.5% in the 3rd quarter. Hanson & Doremus Investment Management now owns 1,813 shares of the biopharmaceutical company’s stock worth $147,000 after acquiring an additional 1,613 shares during the period. Harel Insurance Investments & Financial Services Ltd. lifted its stake in shares of Gilead Sciences by 29.3% in the 2nd quarter. Harel Insurance Investments & Financial Services Ltd. now owns 2,120 shares of the biopharmaceutical company’s stock worth $150,000 after acquiring an additional 480 shares during the period. Rowland & Co. Investment Counsel ADV acquired a new stake in shares of Gilead Sciences in the 2nd quarter worth approximately $153,000. Finally, Capstone Investment Advisors Netherlands B.V. acquired a new stake in shares of Gilead Sciences in the 2nd quarter worth approximately $172,000. Hedge funds and other institutional investors own 75.94% of the company’s stock.
Shares of Gilead Sciences, Inc. (GILD) opened at $78.10 on Wednesday. Gilead Sciences, Inc. has a one year low of $63.76 and a one year high of $86.27. The company has a market cap of $101,990.00, a P/E ratio of 8.89, a P/E/G ratio of -1.58 and a beta of 1.13. The company has a current ratio of 3.68, a quick ratio of 3.56 and a debt-to-equity ratio of 1.10.
Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings results on Thursday, October 26th. The biopharmaceutical company reported $2.27 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $2.13 by $0.14. The business had revenue of $6.51 billion during the quarter, compared to the consensus estimate of $6.40 billion. Gilead Sciences had a net margin of 42.22% and a return on equity of 57.15%. The firm’s quarterly revenue was down 13.2% on a year-over-year basis. During the same quarter in the prior year, the firm earned $2.75 EPS. equities analysts predict that Gilead Sciences, Inc. will post 8.53 EPS for the current year.
The company also recently declared a quarterly dividend, which was paid on Thursday, December 28th. Investors of record on Friday, December 15th were given a $0.52 dividend. The ex-dividend date was Thursday, December 14th. This represents a $2.08 annualized dividend and a dividend yield of 2.66%. Gilead Sciences’s dividend payout ratio (DPR) is presently 23.66%.
A number of analysts have recently weighed in on GILD shares. Vetr raised shares of Gilead Sciences from a “buy” rating to a “strong-buy” rating and set a $91.98 price target for the company in a research note on Friday, October 13th. Berenberg Bank set a $96.00 price target on shares of Gilead Sciences and gave the stock a “buy” rating in a research note on Thursday, October 19th. BMO Capital Markets reduced their price target on shares of Gilead Sciences from $89.00 to $83.00 and set an “outperform” rating for the company in a research note on Friday, October 27th. Credit Suisse Group reaffirmed a “buy” rating and issued a $82.00 price target on shares of Gilead Sciences in a research note on Thursday, December 7th. Finally, Mizuho upped their price target on shares of Gilead Sciences from $77.00 to $83.00 and gave the stock a “buy” rating in a research note on Wednesday, November 8th. Two analysts have rated the stock with a sell rating, thirteen have assigned a hold rating, sixteen have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus price target of $85.03.
In related news, EVP Gregg H. Alton sold 15,000 shares of the company’s stock in a transaction that occurred on Wednesday, November 1st. The shares were sold at an average price of $74.82, for a total value of $1,122,300.00. Following the completion of the sale, the executive vice president now owns 77,363 shares in the company, valued at approximately $5,788,299.66. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, insider John C. Martin sold 73,333 shares of the company’s stock in a transaction that occurred on Wednesday, November 1st. The shares were sold at an average price of $75.13, for a total transaction of $5,509,508.29. Following the completion of the sale, the insider now owns 3,070,099 shares of the company’s stock, valued at approximately $230,656,537.87. The disclosure for this sale can be found here. In the last 90 days, insiders sold 461,666 shares of company stock valued at $34,072,567. 1.30% of the stock is owned by insiders.
Gilead Sciences Profile
Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.
Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD).
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with Analyst Ratings Network's FREE daily email newsletter.